HomeBUSINESS
BUSINESS

MHLW to Use Its Classification Table to Pick PMP-Eligible Similar Drugs; How Will 3 Year 3rd Product Rule Affect I/O and Other Meds?
(Dec.26.2017)

As the so-called price maintenance premium (PMP) for on-patent drugs will see a major reduction in its scope in April 2018, many products are anticipated to lose eligibility on a series of new restrictions, particularly one dubbed the “three year/third product” rule. How will new inclusion and exclusion PMP criteria affect immuno-oncology drugs and other medicines on the market? ...
(LOG IN FOR FULL STORY)